IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Jensen Investment Management Inc.

Jensen Investment Management Inc. lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 11.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,020 shares of the company's stock after purchasing an additional 930 shares during the period. Jensen Investment Management Inc.'s holdings in IDEXX Laboratories were worth $3,729,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in shares of IDEXX Laboratories by 1.8% during the third quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company's stock worth $1,138,732,000 after buying an additional 40,349 shares in the last quarter. Franklin Resources Inc. lifted its stake in IDEXX Laboratories by 2.5% in the third quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock worth $675,259,000 after acquiring an additional 34,305 shares during the last quarter. Amundi grew its holdings in IDEXX Laboratories by 8.1% during the 4th quarter. Amundi now owns 758,669 shares of the company's stock worth $328,018,000 after acquiring an additional 56,837 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of IDEXX Laboratories by 0.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 751,900 shares of the company's stock valued at $379,875,000 after purchasing an additional 2,463 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of IDEXX Laboratories by 3.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 531,692 shares of the company's stock valued at $219,823,000 after purchasing an additional 16,213 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Remove Ads

IDEXX Laboratories Stock Performance

IDXX traded down $1.53 on Thursday, hitting $420.62. 537,534 shares of the company traded hands, compared to its average volume of 549,441. The company has a 50 day moving average of $437.54 and a 200-day moving average of $445.70. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88. The stock has a market capitalization of $34.21 billion, a PE ratio of 39.42, a PEG ratio of 3.41 and a beta of 1.39. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on IDXX. Piper Sandler lifted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Leerink Partners began coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 target price on the stock. Bank of America boosted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Finally, StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, March 15th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and an average target price of $533.75.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.